Cancer diagnostics tests covered in these reports include: ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
These reports also cover information on current and emerging products and review of over 200 current and emerging cancer diagnostic tests including: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others. The reports also provide analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.
Competitive assessments in these reports include information on market players in the industry operating in US, UK, Spain, Japan, Italy, Germany and France. This analysis covers strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Business opportunities and strategic recommendations covered in this research studies include specific new product development opportunities with potentially significant market appeal during the next five years, desig
|SOURCE RnR Market Research|
Copyright©2012 PR Newswire.
All rights reserved